

Introduction

Claudin-18.2 (CLDN18.2) is a tetraspan membrane protein involved in the formation of tight junctions. CLDN18.2 is highly expressed in several cancers, including gastric, esophageal, pancreatic, lung, and ovarian cancers.

CLDN18.2-targeted therapies have shown promising antitumor effects in clinical studies.

Bispecific T cell engager has the potential to improve the therapeutic window and overcome resistance to targeted therapy. Here we report the development of HBM7022, a CLDN18.2 x CD3 bispecific antibody with our HCAb Based Immune Cell Engager (HBICE™) 2+1 platform. HBM7022 induces potent and specific killing of gastric cancer cells in both *in vitro* and *in vivo* studies.